Recent News

• 03.25.2026 - Dyadic Announces 2025 Financial Results and Highlights Recent Company Progress
• 03.16.2026 - Dyadic Applied BioSolutions Announces Commercial Distribution Partnership with IBT Bioservices
• 03.11.2026 - Dyadic to Report 2025 Full Year Financial Results and Host Conference Call on Wednesday, March 25, 2026
• 03.04.2026 - Dyadic and Fermbox Bio Launch First Product Under Expanded Collaboration: Animal-Origin-Free Recombinant DNase I (RNase-Free)
• 03.02.2026 - Dyadic Applied BioSolutions and Inzymes ApS Announce Planned 2026 Commercialization of Non-Animal Dairy Enzyme Following Achievement of Development Milestone
• 02.17.2026 - Dyadic Applied BioSolutions and Proliant Health & Biologicals Announce Commercial Launch of Recombinant Human Albumin
• 12.17.2025 - Dyadic and Fermbox Bio Expand Strategic Collaboration to Accelerate Commercialization of Animal-Free Proteins and Enzymes Across Life Science, Food & Nutrition, and Bioindustrial Markets

Recent Filings

• 03.06.2026 - 424B5 Prospectus [Rule 424(b)(5)]
• 03.06.2026 - 8-K Current report
• 02.17.2026 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 01.06.2026 - 4 Statement of changes in beneficial ownership of securities
• 01.06.2026 - 4 Statement of changes in beneficial ownership of securities
• 01.06.2026 - 4 Statement of changes in beneficial ownership of securities
• 01.06.2026 - 4 Statement of changes in beneficial ownership of securities
• 01.06.2026 - 4 Statement of changes in beneficial ownership of securities
• 01.06.2026 - 4 Statement of changes in beneficial ownership of securities
• 01.06.2026 - 4 Statement of changes in beneficial ownership of securities